BioStock: Saniona’s CEO responds to investors’ questions

Saniona’s collaboration with Acadia Pharmaceuticals, signed in November, marked a significant milestone for the company. With a total potential value of $610 million, it provides crucial funding for ongoing and future research initiatives. Recently, CEO Thomas Feldthus and incoming Chairman of the Board John Haurum visited our studio to address investors’ questions. In this written interview, Feldthus addresses additional questions and those that were not covered during the live session.

Read the full interview with Thomas Feldthus at biostock.se:

https://www.biostock.se/en/2025/02/sanionas-ceo-responds-to-investors-questions/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/